Thursday, 14 February 2019

Molecular Diagnostics Market: Inclination of Leading Players Towards R&D Activities to Bring More Revenues


Molecular diagnostics tests are used for detecting disturbance between specific sequences in DNA or RNA, which may be associated with disease. The disturbance between a single nucleotide polymorphism (SNP), deletions, rearrangements, insertions, and others factors lead to various diseases. Disease that are diagnosed by using molecular diagnostic test includes infectious diseases, oncology, virology, and STDs. Molecular diagnostics are capable of detecting specific disease which helps in providing precision medicine to patients. Government of various economies are focused on research and development of precision medicine, which is expected to drive growth of the molecular diagnostics market over the forecast period. For instance, in 2015, the U.S. government launched Precision Medicine Initiative (PMI), to increase awareness regarding advancement in the precision medicine field.

Download PDF Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1545

High prevalence of infectious disease and increasing incidences of cancer are expected to be the major factor fueling growth of the market over forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2015, around 5,251 deaths were reported due to influenza infection in the U.S. Furthermore, according to a National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer were diagnosed in the U.S. with an estimated 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024.

The molecular diagnostics market is estimated to be valued at US$8,623.2 Mn in 2017 and is expected to witness a robust CAGR of 11.5% during the forecast period (2017-2025).

Market Dynamics

The global molecular diagnostics market is projected to witness significant growth over the forecast period, owing to rapid advancements in technology for development of novel biomarkers. For instance, in June 2017, Qiagen N.V. expanded its biomarker content portfolio by adding new biomarkers for microsatellite instability (MSI) and Mismatch repair (MMR) in its NGS panels. This extension in the product portfolio was done to cater to growing demand for molecular diagnostics for immuno-oncology therapies. Furthermore, precision medicine aids in treatment of diseases and prevention based on individual’s genes, lifestyle, and environment. This helps to offer proper treatment, which has led to high demand for precision medicine, in turn, favoring growth of the market. However, stringent regulation by FDA to regulate molecular diagnostic tests is expected to be major factor restraining growth of the market. The FDA regulates molecular diagnostic tests in various ways, including in some instances, wherein, certain tests require regulatory pathways as complex as Class III medical devices.

Growth in biomarker identification is expected to foster growth of the molecular diagnostics market

Application of biomarkers in molecular diagnostic is increasing, due to advantages of biomarkers such as aiding in early detection of specific diseases. For instance, biomarkers are used in detection of ABO haemolytic diseases in new born, Huntington's disease and hereditary haemochromatosis, and cystic fibrosis. Biomarkers are also used in detection of disorders related to chromosome structure such as Turner syndrome, Down syndrome, patau syndrome, and Edwards’s syndrome. Furthermore, biomarker also have wide application in therapeutic areas, which includes neurological diseases, metabolic disorders, immune deregulation, and oncology.

Regional insights

North America accounts for the largest share in the global molecular diagnostics market and this is attributed to increasing adoption of precision medicine and growing prevalence of cancer. According to a National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer were diagnosed in the U.S., with around 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024, in turn increasing the demand of the molecular diagnostics market in the near future.

Top Key Players

Key players in the market are involved in new product launches to cater to increasing demand for molecular diagnostic. For instance, in August 2016 Abbott Laboratories introduced Alinity, a next generation system, used for immunoassay, clinical chemistry, point-of-care, hematology, blood and plasma screening, and molecular diagnostics. Some of the other key players in the global molecular diagnostics market include Hologic,Inc., Grifols, S.A., Abbott Laboratories, Qiagen N.V., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Becton, Dickinson and Company, and Beckman Coulter, Inc.

Detailed Segmentation:

Global Molecular Diagnostics Market, By Product Type:
- Reagents & Kits (Consumables)
- Instruments

Global Molecular Diagnostics Market, By Application
- Oncology
- Genetic Testing
- Microbiology
- STDs
- Blood Screening
- Virology
- Tissue Typing
- Prenatal Diagnosis
- Others

Global Molecular Diagnostics Market, By End User:
- Hospitals
- Diagnostic Laboratories
- Academic and Research Labs
- Others

Global Molecular Diagnostics Market, By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa

Else place an Inquire before Purchase “Global Molecular Diagnostics Market Size, Status and Forecast 2025": https://www.coherentmarketinsights.com/insight/talk-to-analyst/1545

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702

No comments:

Post a Comment